1Modlin IM, Lye KD, Kidd M. A5-decade analysis of 13,715 carci- noid tumors. Cancer, 2003,97(4):934-959. 被引量：1
2Ahlman H, Nilsson O, Olansson M. Interventional treatment of the carcinoid syndrome. Neuroendocrinology, 2004,80(suppl 1):67-73. 被引量：1
3Moertel CG. Kamofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol, 1987,5(10):1502-1522. 被引量：1
4K16ppel G, Perren A, Heitz PU. The neuroen- docrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci, 2004,1014:13-27. 被引量：1
5Modlin IM, Kidd M, Pfragner R, et al. The functional characteriza- tion of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab, 2006,91(6)2340-2348. 被引量：1
6Williams ED, Sandier M. The classification of carcinoid tumors. Lancet, 1963,1(7275):238-239. 被引量：1
7Merola E, Sbrozzi-Vanni A, Panzuto F, et al.Type I gastric carci- noids :a prospective study on endoscopic management and recur- rence rate. Neuroendocrinology, 2012,95(3):207-213. 被引量：1
8Jensen RT. Peptide therapies: Recent advances in the use of somato- statin and other peptide receptor agonists and antagonists. In: Lewis JH, DuboJs A, editors. Current Clinical Topics in Gastrointestinal Pharmacology. Malden MA: Blackwell Science, 1997:144-223. 被引量：1
9Jensen RT. Presence of somatostatin receptors on gastro enteropan- creatic endocrine tumors (GEP's): Impact on clinical managementwith somatostatin receptor imaging and other uses of somatostatin analysis. In: Lamberts SW, editor. Octreotide: The Next Decade. Bristol, UK: Bioscientific Ltd, 1999:149-78. 被引量：1
10Toth Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg, 2004,187(5):575-579. 被引量：1
